Disulfidptosis in cancer: from redox stress to therapeutic strategy

Cellular survival in neoplastic environments depends heavily on maintaining a precise equilibrium between oxidants and antioxidants within the complex tumor microenvironment (TME). Prior research has shown that tumor cells frequently adapt to high levels of oxidative stress by upregulating protective metabolic pathways to ensure continued proliferation. These adaptations often involve the manipulation of thiol-containing molecules like glutathione (GSH) to prevent irreversible damage to cellular structures and proteins. While apoptosis and ferroptosis are well-characterized, the specific role of disulfide-mediated pathways in oncogenesis remained poorly understood for many years. Researchers previously focused on reactive oxygen species without fully accounting for the impact of accumulated disulfides on the structural integrity of the cytoskeleton. The scientific community lacked a cohesive understanding of how thiol-disulfide exchange imbalance specifically contributes to the vulnerability of malignant cells. This absence of evidence motivated a comprehensive overview of how these specific biochemical imbalances drive a novel form of regulated cell death.

This synthesis evaluates the molecular underpinnings of disulfidptosis and its potential as a target for oncological intervention in various aggressive oncological types. The analysis explores how the redox balance within the tumor microenvironment (TME) influences cancer progression and the subsequent development of treatment insensitivity. Investigators examine the intricate crosstalk between this novel death pathway and established cellular destruction mechanisms to identify potential synergistic effects. The work identifies specific metabolic vulnerabilities, such as glutathione (GSH) depletion, that clinicians might exploit to overcome treatment insensitivity in recalcitrant malignancies. By outlining the current landscape of small-molecule activators, the authors provide a strategic roadmap for future translational research and clinical trial design. This synthesis clarifies the relationship between thiol-disulfide exchange and endoplasmic reticulum (ER) stress in the context of tumor suppression and cell death. The study aims to bridge the gap between basic redox biology and the practical application of cell death induction in clinical oncology.

The researchers conducted a systematic evaluation of current literature regarding disulfide-dependent cell death across various malignancy models and experimental conditions. They aggregated data from studies utilizing inducing compounds to trigger metabolic collapse in cancerous cells by targeting specific redox-sensitive pathways. The investigation incorporates findings from biochemical assays that quantify glutathione (GSH) depletion and its subsequent effect on cellular viability and physical robustness. Analytical structures centered on the interaction between thiol-disulfide exchange imbalance and the induction of endoplasmic reticulum (ER) stress within the tumor microenvironment (TME). The authors categorized translational applications based on their potency in combination therapies and their ability to modulate the immune milieu of the tumor. This methodological approach allowed for a detailed comparison of disulfidptosis against traditional cell death pathways like apoptosis and necroptosis. The investigation also scrutinized the obstacles associated with the clinical translation of these findings into effective patient treatments.

Disulfidptosis emerges as a distinct form of regulated cell death driven primarily by the depletion of glutathione (GSH) and the resulting metabolic stress. The resulting thiol-disulfide exchange imbalance triggers severe endoplasmic reticulum (ER) stress, leading to the rapid loss of tumor cell viability and cytoskeletal breakdown. Evidence suggests that this pathway serves as a key regulator of both cancer progression and the development of therapy resistance in multiple tumor types. The review highlights that pharmacological agents can successfully trigger this process, offering a new avenue for treating tumors that are resistant to conventional therapies. Combination therapies involving these activators show enhanced efficacy when measured against monotherapeutic approaches in various preclinical systems of aggressive cancer. The molecular mechanisms identified link the redox state of the tumor microenvironment (TME) directly to the induction of this disulfide-dependent process. These findings demonstrate that targeting the disulfide-dependent pathway can effectively bypass the anti-apoptotic mechanisms frequently employed by malignant cells.

The identification of disulfidptosis provides a promising framework for developing next-generation cancer therapeutics that exploit the unique metabolic vulnerabilities of malignant cells. Targeting the redox vulnerabilities of the tumor microenvironment (TME) may circumvent existing resistance to traditional chemotherapy and radiation in clinical settings. Future research must address the significant challenges associated with the clinical translation of small-molecule activators, including bioavailability and off-target effects. Investigators should prioritize the discovery of biomarkers that predict sensitivity to disulfide-dependent cell death in diverse patient populations to enable personalized treatment strategies. The integration of these findings into clinical practice could fundamentally alter the management of aggressive malignancies by providing new tools for cell death induction. This review underscores the necessity of exploring the synergistic effects of disulfidptosis induction alongside established immunotherapy protocols to maximize patient outcomes. Ultimately, the study positions disulfide-mediated cell death as a cornerstone of future oncological strategies aimed at overcoming clinical recalcitrance.